Core Viewpoint - The article discusses the critical role of bile acids in digestion, energy metabolism, and hormone signaling, highlighting the importance of the Ostα/β transport protein in the enterohepatic circulation of bile acids and its unique transport mechanism [2][3][11]. Group 1: Research Findings - A research team from the Shanghai Institute of Materia Medica and affiliated hospitals published a study in Nature revealing the unique structure and transport mechanism of the Ostα/β protein [3]. - The study utilized cryo-electron microscopy, molecular dynamics simulations, and electrophysiological analysis to elucidate the three-dimensional structure and substrate recognition patterns of Ostα/β [3][4]. - The Ostα/β complex was successfully expressed and purified, showing a symmetric tetrameric assembly with a novel seven-transmembrane helix folding pattern [4]. Group 2: Mechanism of Action - The structural analysis identified a substrate-binding groove near the cytoplasmic side of the membrane, which is modified by palmitoylation, creating a microenvironment suitable for binding amphipathic steroid molecules [5]. - The research demonstrated that Ostα/β interacts with physiological substrates, such as taurocholic acid and dehydroepiandrosterone sulfate, through specific electrostatic interactions [5]. - A hydrophilic channel extending from the binding groove to the extracellular side was identified, suggesting a pathway for substrate translocation across the membrane [5]. Group 3: Physiological Implications - The study introduced a novel method to monitor bile acid transport in real-time using whole-cell patch-clamp techniques, demonstrating that the transport direction of Ostα/β is influenced by the electrochemical gradient across the membrane [8][9]. - The findings indicate that membrane potential is a key regulatory factor that biases the transport direction, enhancing the understanding of bile acid excretion under different physiological conditions [9]. Group 4: Clinical Relevance - The research fills a critical gap in understanding bile acid excretion in the enterohepatic circulation, providing insights for potential therapeutic interventions in liver and biliary diseases [11]. - Dysregulation of bile acid metabolism is linked to various liver diseases, and targeting Ostα/β could offer a direct approach to modulate bile acid distribution and alleviate related pathologies [11]. - The structural comparison suggests that Ostα/β may belong to a new class of transport proteins, opening new avenues for research on the TMEM184 protein family and its potential disease associations [11].

Core Viewpoint - Bile acids (BAs) play a crucial role in nutrient absorption, lipid metabolism, and immune regulation, with their transport and distribution in the body being tightly regulated by specific membrane proteins [2][3]. Group 1: Bile Acid Transport Mechanism - The enterohepatic circulation of bile acids relies on the coordinated action of four key transport proteins: ASBT, OSTα/β, NTCP, and BSEP, which are essential for bile acid uptake and recycling [3]. - OSTα/β, a unique member of the solute carrier (SLC) family, requires assembly of α and β subunits to function and can transport bile acids bidirectionally, unlike other transporters that operate as monomers [3][8]. Group 2: Research Findings - A recent study published in Nature by a team from the Chinese Academy of Sciences and Peking University revealed the high-resolution cryo-EM structure of the OSTα/β complex, providing insights into its assembly and transport mechanism [4][5]. - The study identified a unique "2+2" heterotetramer assembly of OSTα/β, with tight interactions between α-β and α-α interfaces enhancing the stability of the complex [8]. - The research also discovered a bile acid binding pocket that facilitates the transport process without significant conformational changes, proposing a novel transport mechanism that relies on a half-embedded membrane channel [8].

Core Viewpoint - The biomanufacturing sector is recognized as a key engine for the new technological revolution and industrial transformation, with Changde aiming to establish itself as a national-level industrial cluster by 2025 [1][4]. Group 1: Industry Development - Changde has nurtured several biopharmaceutical companies, including YunGang Bio and LiEr Bio, with 35 core enterprises in synthetic biomanufacturing expected to achieve a production value exceeding 7.5 billion yuan by mid-2025 [1][4]. - YunGang Bio has developed a GMP-standard automated production line for extracting and synthesizing ursodeoxycholic acid from animal bile, achieving a conversion rate of over 99% and capturing more than one-third of the domestic market for its core product [2][3]. - Changde's synthetic biomanufacturing industry has shown significant growth, with a production value of 7.689 billion yuan as of July 2025, reflecting a year-on-year increase of 23.52% [3]. Group 2: Technological Innovation - The foundation of synthetic biology and biomanufacturing is held by companies like MuEn Bio, which has identified over 320,000 proprietary microbial strains, enabling high-throughput screening for bioactive microorganisms and their metabolites [2][3]. - MuEn Bio has established a comprehensive DREAM technology platform that covers the entire process from resource discovery to product development, enhancing its competitive edge in biomanufacturing [3]. Group 3: Ecosystem and Support - Changde is building a comprehensive industrial ecosystem with support from policies, talent acquisition, and financial backing, aiming to accelerate the transition from technological breakthroughs to large-scale implementation [4][5]. - The establishment of a 5 billion yuan biomanufacturing mother fund and a 1 billion yuan innovation guidance fund is part of Changde's strategy to inject "patient capital" into the biomanufacturing sector [4]. Group 4: Future Prospects - By 2028, Changde aims to achieve a production value of over 30 billion yuan in synthetic biomanufacturing and to cultivate more than 100 enterprises in the sector, including over 50 high-tech companies [6]. - The biomanufacturing industry in China has reached a total scale of nearly 1 trillion yuan, with fermentation capacity accounting for over 70% of the global market, indicating significant growth potential [5][6].